Dostarlimab Wins Accelerated FDA Approval in dMMR Locally Advanced Rectal Cancer
The FDA has granted accelerated approval to dostarlimab-gxly for adults with previously untreated stage II or stage III locally advanced rectal cancer whose tumors are mismatch repair deficient, or MSI-H, opening a route that may spare selected patients from chemotherapy, radiation, and surgery. For a disease in which treatment often reshapes bowel, urinary, sexual, and fertility function for years, the approval marks a notable shift in how early rectal cancer can be approached when the biology is unusually immunotherapy-sensitive.
This is not a broad rectal cancer approval. It is tightly restricted to tumors with a defined DNA repair defect, a small subgroup in which malignant cells accumulate errors faster than the immune system can ignore them. In these cancers, deficient mismatch repair allows replication mistakes to persist, generating abnormal proteins that make the tumor more visible to immune surveillance. Blocking PD-1 with dostarlimab removes one of the brakes cancer uses to silence T-cell activity, and that mechanism fits the unusually deep responses seen in this setting.
The practical implication is immediate for a narrow population: some patients may now begin with immunotherapy alone instead of moving directly into the familiar sequence of chemoradiation and total mesorectal excision. For rectal cancer, that matters because the standard path can leave permanent bowel dysfunction, sexual dysfunction, infertility, or a permanent colostomy. Surgery also carries the risk of poor healing and anastomotic leak, complications that can be life-threatening and often extend hospitalization and recovery well beyond the operation itself.
Interim AZUR-1 Data Drove the Decision
The approval rests on interim findings from AZUR-1, a phase 2 study that enrolled 154 patients with previously untreated dMMR or MSI-H locally advanced rectal cancer. Participants received up to nine doses of dostarlimab every 3 weeks over 6 months. After a median follow-up of more than 2 years, almost three-fourths of patients had not required surgery, radiotherapy, or chemotherapy.
That outcome is the clearest signal in the dataset. Instead of measuring success only by tumor shrinkage before a planned operation, the study asked whether the entire conventional treatment sequence could be avoided, and many patients did not proceed to those next steps at all. In a disease where local control has traditionally been pursued through escalating multimodality therapy, the ability to halt at immunotherapy alone reflects a genuine biologic divergence between this tumor subtype and the typical rectal cancer population.
Because the approval is accelerated, it is not the end of the evidence chain. Longer follow-up is still needed to determine how durable these responses remain and how often relapse occurs after treatment cessation. The FDA has made clear through this pathway that interim efficacy can justify earlier access, but the sponsor must continue monitoring patients to establish lasting clinical benefit.
Prior MSK Experience Was Consistent With Deep Tumor Clearance
An earlier single-center study at Memorial Sloan Kettering Cancer Center provides an important clinical anchor. In that trial, 50 patients with previously untreated dMMR or MSI-H locally advanced rectal cancer received dostarlimab alone. None had detectable signs of cancer after treatment, and nearly all maintained cancer-free status for at least 12 months. Among the 27 patients followed for at least 3 years, only one experienced recurrence, and the recurrence appeared in the same area.
Those results help explain why immunotherapy is drawing attention in this disease. dMMR and MSI-H tumors carry a heavy mutational burden, which creates multiple abnormal antigenic targets for the immune system. Once PD-1 inhibition releases exhausted T cells, the biologic pressure on the tumor can be profound enough to clear visible disease without the tissue destruction that accompanies radiation or surgery. The durability seen in the longer-followed subset suggests that some patients may achieve more than a temporary response, though the FDA approval still depends on expanded observation rather than certainty.
Safety Remains the Constraint on Broad Use
Immune-mediated toxicity can be severe or fatal.
Dostarlimab can trigger the immune system to attack healthy organs and tissues, and that risk remains central to prescribing. The most common adverse effects reported in at least 15% of patients treated for this rectal cancer indication were fatigue, rash, diarrhea, and itching. Those toxicities are familiar for checkpoint blockade, but the possibility of more serious immune-related injury means clinicians still need close surveillance for colitis, hepatitis, endocrinopathies, pneumonitis, and other organ-threatening reactions even when treatment is being used to avoid more toxic local therapy.
The safety profile also frames the decision-making conversation. Patients may be weighing a finite course of immunotherapy against a path that could otherwise include radiation-induced pelvic injury, major surgery, and permanent changes in quality of life. In the dMMR/MSI-H subgroup, the balance may favor starting with PD-1 blockade, but the tradeoff is not zero-risk treatment; it is a different kind of risk, one centered on immune activation rather than tissue destruction.
Regulatory Pathway Signals Confidence, Not Finality
The FDA granted Priority Review and Breakthrough Therapy designation to the application, and this decision marks the 11th approval reviewed under the Commissioner’s National Priority Voucher pilot program. The action also reflects a broader regulatory willingness to move quickly when a treatment shows clear potential to change the treatment burden for a serious cancer with few biologically targeted options.
Even with that regulatory momentum, the evidence base remains purposefully narrow. The drug is approved only for adults with previously untreated stage II or stage III locally advanced rectal cancer whose tumors are confirmed as dMMR or MSI-H by an FDA-authorized test. Published estimates suggest that roughly 3% of locally advanced rectal cancers fall into that category, so most patients with rectal cancer will not qualify for this approach.
Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence, described the approval as a significant benefit for patients and families while emphasizing that further studies are needed to verify lasting outcomes. That is the key tension in the decision: an unusually strong early response has justified access, but the long arc of disease control still has to be proven in follow-up. For now, the approval changes the first conversation for a very specific group of patients, while the remaining questions center on durability, recurrence patterns, and how often this nonoperative strategy can safely replace the standard course of rectal cancer treatment.